Joel Lewis, President and CEO at GALECTIN THERAPEUTICS INC (GALT), sold 30,140 shares at $6.07 ($183K) on 2025-11-04, disclosed to the SEC on 2025-11-05.
Scheduled sale ($183k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.01 | 1,300 | $8K | 4.3% |
| 2 | $6.07 | 14,420 | $88K | 47.9% |
| 3 | $6.07 | 14,420 | $88K | 47.9% |
| Total | $6.07 avg | 30,140 | $183K | 100% |
| Filing → |
| GALT | SELL | 2025-11-19 | $231K | — | Filing → |
| GALT | SELL | 2025-11-12 | $11K | — | Filing → |
| GALT | SELL | 2025-11-07 | $1K | — | Filing → |